La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Agios Pharmaceuticals Gestione
Gestione criteri di controllo 4/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Brian Goff
Amministratore delegato
US$3.4m
Compenso totale
| Percentuale dello stipendio del CEO | 23.4% |
| Mandato del CEO | 2yrs |
| Proprietà del CEO | 0.1% |
| Durata media del management | 2.6yrs |
| Durata media del Consiglio di amministrazione | 8.2yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 04
Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline
Jun 12Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth
Jun 02Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates
Feb 17Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Jan 16Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%
Nov 09Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Sep 26Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?
May 08We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely
Feb 06Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans
Oct 18Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU
Sep 16Agios adds more than 13% after Novo deal to acquire rival Forma
Sep 01Agios Pharmaceuticals GAAP EPS of -$1.68 beats by $0.07
Aug 04Agios Pharmaceuticals Is A Buy On Coming Revenue Ramp
Jul 26Agios Pharmaceuticals appoints new board chair, CEO
Jul 12Agios: Approved Product, Upcoming Catalysts
May 10Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?
May 10Agios Pharmaceuticals With FDA Approval Is A Buy
Feb 23Agios Before The February PDUFA
Jan 20Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 46%
Dec 21Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$365m |
| Mar 31 2024 | n/a | n/a | -US$353m |
| Dec 31 2023 | US$3m | US$798k | -US$352m |
| Sep 30 2023 | n/a | n/a | -US$220m |
| Jun 30 2023 | n/a | n/a | -US$210m |
| Mar 31 2023 | n/a | n/a | -US$218m |
| Dec 31 2022 | US$12m | US$308k | -US$232m |
Compensazione vs Mercato: La retribuzione totale di Brian ($USD 3.42M ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 6.76M ).
Compensazione vs guadagni: La retribuzione di Brian è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Brian Goff (55 yo)
2yrs
Mandato
US$3,416,453
Compensazione
Mr. Brian M. Goff, M.B.A., is Independent Director of Intellia Therapeutics, Inc. from June 2024. He is Chief Executive Officer and Director at Agios Pharmaceuticals, Inc. from August 08, 2022. He had been...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 2yrs | US$3.42m | 0.14% $ 3.7m | |
| Chief Financial Officer | 1.9yrs | US$1.21m | 0.026% $ 698.9k | |
| Corporate Secretary & Chief Legal Officer | 2.6yrs | US$1.93m | 0.065% $ 1.8m | |
| Chief Medical Officer and Head of Research & Development | 2.9yrs | US$2.87m | 0.077% $ 2.1m | |
| Chief Commercial Officer | 1.6yrs | US$3.73m | 0.023% $ 623.3k | |
| Co-Founder & Member of Scientific Advisory Board | no data | US$333.51k | Nessun dato | |
| Co-Founder & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Co-Founder & Chairman of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Co-Founder & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| VP, Controller & Principal Accounting Officer | 3yrs | Nessun dato | 0.0027% $ 71.8k | |
| Chief Technical Operations Officer | 7.2yrs | Nessun dato | Nessun dato | |
| Vice President of Investor Relations & Corporate Communications | no data | Nessun dato | Nessun dato |
2.6yrs
Durata media
55yo
Età media
Gestione esperta: Il team dirigenziale di AGIO è considerato esperto (durata media dell'incarico 2.6 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 2yrs | US$3.42m | 0.14% $ 3.7m | |
| Co-Founder & Member of Scientific Advisory Board | no data | US$333.51k | Nessun dato | |
| Co-Founder & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Co-Founder & Chairman of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Co-Founder & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Chair of the Board of Directors | 6.7yrs | US$447.25k | 0.25% $ 6.6m | |
| Independent Director | 1.2yrs | US$663.68k | 0.0035% $ 93.0k | |
| Member of Scientific Advisory Board | 15.5yrs | Nessun dato | Nessun dato | |
| Lead Independent Director | 9.7yrs | US$440.95k | 0.013% $ 355.6k | |
| Independent Director | 15yrs | US$417.25k | 0.84% $ 22.4m | |
| Member of Scientific Advisory Board | 15.8yrs | Nessun dato | Nessun dato | |
| Independent Director | 2yrs | US$419.91k | 0.014% $ 376.5k |
8.2yrs
Durata media
65yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AGIO sono considerati esperti (durata media dell'incarico 8.2 anni).